Syngen BiotechLtd Balance Sheet Health
Financial Health criteria checks 6/6
Syngen BiotechLtd has a total shareholder equity of NT$2.2B and total debt of NT$237.7M, which brings its debt-to-equity ratio to 10.9%. Its total assets and total liabilities are NT$3.0B and NT$818.7M respectively. Syngen BiotechLtd's EBIT is NT$305.1M making its interest coverage ratio 40.9. It has cash and short-term investments of NT$228.3M.
Key information
10.9%
Debt to equity ratio
NT$237.73m
Debt
| Interest coverage ratio | 40.9x |
| Cash | NT$228.31m |
| Equity | NT$2.18b |
| Total liabilities | NT$818.68m |
| Total assets | NT$3.00b |
Recent financial health updates
Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?
Mar 25
Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly
Dec 16
Recent updates
Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?
Mar 25Should Syngen Biotech Co., Ltd. (GTSM:8279) Be Part Of Your Dividend Portfolio?
Feb 25Did You Miss Syngen Biotech's (GTSM:8279) Impressive 104% Share Price Gain?
Feb 04Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?
Jan 14Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly
Dec 16Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?
Nov 25Financial Position Analysis
Short Term Liabilities: 8279's short term assets (NT$1.0B) exceed its short term liabilities (NT$471.7M).
Long Term Liabilities: 8279's short term assets (NT$1.0B) exceed its long term liabilities (NT$346.9M).
Debt to Equity History and Analysis
Debt Level: 8279's net debt to equity ratio (0.4%) is considered satisfactory.
Reducing Debt: 8279's debt to equity ratio has reduced from 17.5% to 10.9% over the past 5 years.
Debt Coverage: 8279's debt is well covered by operating cash flow (143.8%).
Interest Coverage: 8279's interest payments on its debt are well covered by EBIT (40.9x coverage).